Tuesday, September 29, 2026
BTC $83,214 ▼ 0.50%
Subscribe
Menu
NewsLive WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
MoreDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
LIVE
ADA$0.244down−0.31%ETH$2,668down−0.31%LINK$14.36down−1.61%SOL$119.06down−0.04%BTC$83,214down−0.50%XRP$1.49up+0.13%S&P 5007,671down−0.17%Nasdaq26,798down−0.09%Dow51,350down−0.26%RUT2,808down−0.35%TNX5.25%up+0.29%TYX5.59%up+0.59%FVX5.06%down−0.10%IRX4.07%up+0.20%VIX16.04down−0.19%GOLD$4,210.40up+0.73%SILVER$61.47up+0.52%OIL$89.63up+0.28%DXY101.35down−0.02%NVDA$227.21down−0.72%AAPL$329.40down−2.66%TSLA$352.84down−1.29%META$738.79up+3.24%MSFT$508.96down−0.05%AMZN$246.67up+0.21%GOOGL$340.92down−0.53%Fear & Greed71 — GreedADA$0.244down−0.31%ETH$2,668down−0.31%LINK$14.36down−1.61%SOL$119.06down−0.04%BTC$83,214down−0.50%XRP$1.49up+0.13%S&P 5007,671down−0.17%Nasdaq26,798down−0.09%Dow51,350down−0.26%RUT2,808down−0.35%TNX5.25%up+0.29%TYX5.59%up+0.59%FVX5.06%down−0.10%IRX4.07%up+0.20%VIX16.04down−0.19%GOLD$4,210.40up+0.73%SILVER$61.47up+0.52%OIL$89.63up+0.28%DXY101.35down−0.02%NVDA$227.21down−0.72%AAPL$329.40down−2.66%TSLA$352.84down−1.29%META$738.79up+3.24%MSFT$508.96down−0.05%AMZN$246.67up+0.21%GOOGL$340.92down−0.53%Fear & Greed71 — Greed
Tag

healthcare stocks

3 articles

JNJ, PEP, BDX, KO: Dividend Kings Offer 2-4% Yields at Attractive Valuations
U.S. Equities38d ago
JNJ, PEP, BDX, KO: Dividend Kings Offer 2-4% Yields at Attractive Valuations
Healthcare and consumer staples Dividend Kings trading above historical yields as equity markets approach new highs, creating defensive entry points for portfolio construction.
Druckenmiller's Natera Bet Pays Off: NTRA Up 37% on Japan Approval, Q2 Beat
U.S. Equities40d ago
Druckenmiller's Natera Bet Pays Off: NTRA Up 37% on Japan Approval, Q2 Beat
Stanley Druckenmiller's Duquesne Family Office holds 16.6 percent of its portfolio in Natera, valued at $865 million, after the diagnostics stock surged on Japanese regulatory approval and strong earnings.
Jefferies Initiates Freenome With Buy, Sees 47% Upside in Cancer Screening
U.S. Equities43d ago
Jefferies Initiates Freenome With Buy, Sees 47% Upside in Cancer Screening
Jefferies set a $17 price target on Freenome (FRNM), trading at $11.56, citing the company's cancer screening potential as the core catalyst